AstraZeneca to acquire Pearl Therapeutics

Joe Goldman |

AstraZeneca (AZN) announced on Monday that it has reached a definitive agreement to acquire respiratory drug specialist Pearl Therapeutics. The deal could be worth up to $1.15 billion and is meant to reload AstraZeneca’s dwindling pipeline.

The privately held, Redwood City, California-based Pearl is best known for asthma and chronic obstructive pulmonary disease (COPD) treatments. Under the terms of the deal, Pearl will receive an initial payment of $560 million, an additional $440 million if it reaches certain development and regulatory milestones, and an extra $140 million if it hits undisclosed sales numbers. The deal is expected to close in the third quarter of 2013.



AstraZeneca has recently faced steep competition from many generic drug manufactures and seems to be having some pipeline issues. Many of its key products have lost patent protection, prompting sales and earnings to fall.

AstraZeneca may be struggling with organic growth, but the company seems confident that it can bolster its pipeline and long-term earnings through acquisitions. This marks AstraZeneca’s second acquisition in two weeks, following its purchase of Omthera Pharmaceuticals for $443 million. It remains unclear if AstraZeneca’s buying spree is over.

However, AstraZeneca must find a way to restore organic growth to appease investors. While shares are up 25 percent over the last 12 months, AstraZeneca has traded flat over the last two years and are well below 2006 highs.

Investors were indifferent to the acquisition news on Monday, as shares were unchanged during afternoon trading at $51.49.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer

Companies

Symbol Name Price Change % Volume
AZN Astrazeneca PLC 28.61 0.03 0.10 5,519,809
UVV Universal Corporation 69.80 3.10 4.65 381,752

Comments

Emerging Growth

Star Navigation Systems Group Ltd.

Star Navigation Systems Group Ltd is engaged in the development, marketing and promotion of in-flight safety monitoring systems.

Private Markets

WayBetter

The spark hit Jamie when he saw co-workers competing to lose weight. Instead of pizzas and subs, they were eating salads and jogging along the river. Some were sneakily leaving…

Santo Diablo Mezcal

Santo Diablo Mezcal has been created to capitalize on a boom sector of the beverage market currently full of many small unmemorable products by producing one sexy, household, easily recognizable…